Cut through all the #$%$ and this is a true winner!!
Gale will pop again soon--
Game Changer... Genentech needs this drug badly. Herceptin off-patent next year.
The time to buy was today at $2.65. We won't see that price ever again.
Not only will NeuVax help prevent re-occurrence, it will serve as a vaccine for anyone that is predisposed. I.e. Family History, Gene Markers, Etc. Makes that potential market even bigger. WOW!
What analyst has a buy rating and $3 target? Once Gale crosses $3 tomorrow, they will have to raise their target or switch their buy opinion. With 7 other analysts with a buy rating and higher price targets, they have to raise the target price. IMO
They would become part of the deal. Gale's current share price should reflect the value of rxii, but it does feel like the market doesn't recognize that company's $70 MM value.
Still way too early to short. I'll be watching this one closely. B/c when the bubble pops, you have to move quick.
Normally, you have to maintain a cash / equity position in the account that exceeds 150 percent of the stock that is shorted. Those percentages change for initial short and ongoing. Also. The percentage may vary depending on the type of security that you hold short. Google reg t for short sales.
Long story short... If the price of the security rises that you hold short, you either have to add more cash into the account or cover your position, I.e. buy back the stock.
The Mötley Fool just said AstraZeneca or Pfizer. So, many potential suitors!